Multiple Sclerosis Drugs Market is expected to show significant growth over the forecast period 2018-2025

Market Synopsis:
Multiple Sclerosis (MS) is a chronic, demyelinating, inflammatory, and an autoimmune disease of the central nervous system. MS disrupts communication between the brain and other parts of the body, resulting in a range of signs and symptoms such as physical, mental, and sometimes psychiatric problems. Some of the particular symptoms are double vision, blindness in one eye, muscle weakness, trouble with sensation. In young adults, it is among the most common causes of neurological disability. MS affects the insulating covers of nerve cells in the brain, hence resulting in a damage to the spinal cord. MS occurs more frequently in women as compared to men. As the disease advances, permanent neurological problems often remain; although during attacks, symptoms may disappear completely.
It is still unclear how MS occurs; proposed causes for this include genetics and environmental factors, for instance, being triggered by a viral infection. Usually, MS is diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.

According to U.S. FDA, most people with MS experience their first symptoms between the ages of 20 to 40s, like vision problems or muscle weakness. The U.S. FDA further states that there are 8,000 to 10,000 children and adolescents in the U.S. suffering from MS. A number of new treatments and diagnostic methods are under development.

The clinical trial was conducted for evaluating the effectiveness of Gilenya in treating pediatric patients with MS. Total number of 214 evaluated patients aged 10 to 17 were taken. Comparison of Gilenya to another MS drug, interferon beta-1a was done. As per the study, after 24 months of treatment, 86 percent of patients receiving Gilenya remained relapse-free, in comparison to 46 percent of receiving interferon beta-1a.

There is no known permanent cure solution for multiple sclerosis. Physical therapy improves the patient’s ability to function. Improvement is seen more in the females. But the long-term outcome is difficult to predict. Life expectancy of MS patient is on average 5 to 10 years lower than that of unaffected ones.
Multiple sclerosis is the most common immune-mediated disorder which affects the central nervous system. In 2015, Lancet published that approximately 2.3 million people were affected globally with rates varying widely in different regions and among different populations. The disease usually begins between the ages of 20 and 50. 

Get a Sample Copy of this Report @

Factors Influencing Market Scenario:
It is estimated that around 116,000 people in England, of which, about 40,000 have relapsing-remitting MS. Approximately, 2.5 million people are affected by multiple sclerosis, according to the Multiple Sclerosis Foundation. 

Rising incidences of multiple sclerosis is one of the important drivers for Multiple Sclerosis Drugs Market. Growing initiative and support from the government about MS will drive the market. In addition, Research & Development initiatives, undertaken by the pharmaceutical companies are the key factors fueling the growth of the market. Moreover, advancements in biomedical science will create a lucrative opportunity for drug makers in the near future. The rising mergers and acquisitions between these vendors and the ongoing product launches will also have a major impact on the market in the coming years.

Regional analysis:
Geographies analyzed in this research report includes major four regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA). In the Asia Pacific region, China and India are expected to witness the fastest growing markets. Some of the key driving factors in the emerging countries are the availability of large talent pool, low wages, and less stringent environment, health, and safety regulations. North America is expected to dominate the market followed by European countries, for instance, Germany, Italy, France, Spain and U.K., which holds a major share of the market in this region. 

Key Players: 
The global Multiple Sclerosis Drugs market comprises some of the key players such as AB Science Abbvie, Bayer Healthcare, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Opexa, Pfizer, Sanofi-Aventis and Teva Pharmaceuticals.

Check Discount for this Report @

Recent Developments:
 In May 2018, National Institute for Health and Care Excellence (NICE) has published a draft guidance for people with the type of MS called relapsing-remitting multiple sclerosis (MS), recommending interferon beta-1b (Extavia, Novartis), glatiramer acetate (Copaxone, Teva UK Ltd), and interferon beta-1a (Avonex, Biogen Idec Ltd, and Rebif, Merck Serono Ltd) as treatment options. Three multiple sclerosis (MS) drugs were reduced, as a result of which NICE  recommended them for routine NHS funding. Hence, more options are available for treatment with relapsing-remitting MS.
 In May 2018, to treat relapsing multiple sclerosis (MS) in children and adolescents of age 10 years and more, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod). To treat MS in pediatric patients, this is the first FDA approval. In 2010, FDA approved Gilenya to treat adults with relapsing MS. Novartis got the approval of Gilenya from the FDA. Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, stated that this approval represents an important and needed advance in the care of pediatric patients with MS.
 In May 2018, Journal of Neurology published a research study which states that Alemtuzumab effectively reduced disease activity for patients with relapsing-remitting multiple sclerosis (RRMS) with refractory disease activity despite fingolimod treatment. The study included clinical and magnetic resonance imaging data from 9 large German MS centers.

Multiple Sclerosis Drugs Market Segmentation
By Drug Class: 
• Immunomodulators
o Ampyra
o Avonex/Plegridy
o Betaseron/Extavia
o Copaxone
o Gilneya
o Rebif
o Tecifidera
o Tysabri
• Immunosuppressant
o Aubagio
o Lemtrada 
o Ocrelizumab
o Zinbryta

By Mode of Administration: 
• Injectable
• Intravenous
• Oral

• Regions Covered:
o North America (U.S and Canada)
o Europe (Germany, France, Italy and Rest of Europe)
o Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
o LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

About Us:

Reports Monitor is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries including Healthcare, Technology, Chemicals, Materials, and Energy. With an intrinsic understanding of many business environments, Reports Monitor provides strategic objective insights.

We periodically update our market research studies to ensure our clients get the most recent, relevant, and valuable information. Reports Monitor has a strong base of analysts and consultants from assorted areas of expertise. Our industry experience and ability to zero-in on the crux of any challenge gives you and your organization the ability to secure a competitive advantage.

Media Contact
Company Name: Reports Monitor
Contact Person: Jay Matthews
Email: Send Email
Phone: +1 513 549-5911
Country: India